Publicacións en colaboración con investigadores/as de Hospital General Universitario de Valencia (3)

2024

  1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

2016

  1. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

    Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579

  2. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1